Cipla Eyes Generic Challenge To Sanofi-Synthelabo's Plavix
Indian generic drug maker Cipla is planning to apply for approval to sell its version of Sanofi-Synthelabo's Plavix, the blood-thinning drug already at the center of Sanofi's drawn-out patent litigation against...To view the full article, register now.
Already a subscriber? Click here to view full article